OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WARSAW, Ind., Oct. 17, 2023 (GLOBE NEWSWIRE) --  OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2023 financial results on Monday, November 6, 2023, after the market closes. OrthoPediatrics will host a conference call on Tuesday, November 7, 2023, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Third Quarter 2023 Financial Results on November 7, 2023

OrthoPediatrics (KIDS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in OrthoPediatrics (KIDS): Can Its 8.1% Jump Turn into More Strength?

WARSAW, Ind., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, has announced a strategic partnership with Children's National Hospital in Washington, DC under the “Alliance for Pediatric Device Innovation” (APDI), to advice the development and commercialization of medical devices designed for children.

OrthoPediatrics Joins Alliance for Pediatric Device Innovation

WARSAW, Ind., Oct. 10, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the limited release of the DF2® Brace as part of its expansion in the non-surgical business for treating kids with musculoskeletal injuries.

OrthoPediatrics Corp. Launches DF2 Brace®

WARSAW, Ind., Sept. 25, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, OrthoPediatrics was a proud sponsor of the 58th Annual Meeting for the Scoliosis Research Society held in Seattle, Washington, on September 6-9th. The Scoliosis Research Society (“SRS”) is an international organization dedicated to the education, research and treatment of Spinal Deformity. This surgical society, and its Annual Meeting are directly aligned with OrthoPediatrics' cause of helping children with pediatric orthopedic conditions. Our sponsorship of the premiere event represented our on-going commitment to the training and education of our clinical partners, as well as a tremendous learning opportunity for how our organization can better service the unique needs of Pediatric Orthopedic Surgeons and patients with scoliosis.

OrthoPediatrics was a Gold Level Sponsor of the Scoliosis Research Society 58th Annual Meeting

WARSAW, Ind., Sept. 14, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Company Showcase on Thursday, September 21, 2023.

OrthoPediatrics Corp. to Participate at the Gilmartin Group Emerging Growth Company Showcase

WARSAW, Ind., Sept. 11, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Pediatric Nailing Platform | Tibia (“PNP Tibia”) surgical system.

OrthoPediatrics Corp. Receives FDA 510(k) Clearance for Pediatric Nailing Platform | Tibia

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Trip Taylor - Investor Relations, Gilmartin Group David Bailey - President and Chief Executive Oficer Fred Hite - Chief Financial Officer and Chief Operating Officer Conference Call Participants Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler David Saxon - Needham and Company Dave Turkaly - JMP Securities Sam Brodovsky - Truist Securities Operator Good morning, and welcome to OrthoPediatrics Corporation's Second Quarter 2023 Earnings Conference Call. At this time all participants' are in listen-only mode.

OrthoPediatrics Corp. (KIDS) Q2 2023 Earnings Call Transcript

While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, OrthoPediatrics (KIDS) Q2 Earnings: A Look at Key Metrics

WARSAW, Ind., July 31, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2023.

OrthoPediatrics Corp. Reports Second Quarter 2023 Financial Results

OrthoPediatrics (KIDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OrthoPediatrics (KIDS) Expected to Beat Earnings Estimates: Should You Buy?

WARSAW, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2023 financial results on Monday, July 31st, 2023, after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 1, 2023, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Second Quarter 2023 Financial Results on August 1, 2023

The GIRO Growth Modulation System by OrthoPediatrics (KIDS) introduces a tether device designed specifically for pediatric patients.

OrthoPediatrics (KIDS) Unveils GIRO for Pediatric Orthopedics

WARSAW, Ind., June 27, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the limited launch and the completion of the first clinical case using the new GIRO Growth Modulation System.

OrthoPediatrics Corp. Announces the Launch and First Case Using the GIRO™ Growth Modulation System

WARSAW, Ind., June 15, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that George Dyer, MD was elected to the Company's Board of Directors at its Annual Meeting of Stockholders held on June 14, 2023.

OrthoPediatrics Announces Election of George Dyer, MD to its Board of Directors

WARSAW, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced the launch of their new Power System for the RESPONSE™ Scoliosis portfolio. The RESPONSE Power System is a complete portfolio of instruments for tapping pedicles, inserting screws, and final tightening of set screws. RESPONSE Power is compatible with OrthoPediatrics' entire suite of fusion implant systems, including RESPONSE 4.5/5.0and RESPONSE 5.5/6.0 fusion systems, and BandLoc – a sublaminar banding technology. This represents the company's 49th system for pediatric orthopedic care.

OrthoPediatrics Corp. Announce Launch of RESPONSE™ Power Scoliosis System

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q1 2023 Results Conference Call May 2, 2023 8:00 AM ET Company Participants Trip Taylor - IR, Gilmartin Group David Bailey - President and CEO Fred Hite - COO and CFO Conference Call Participants Rick Wise - Stifel Ryan Zimmerman - BTIG Mike Matson - Needham & Company Sam Brodovsky - Truist Operator Good morning and welcome to OrthoPediatrics Corporation's First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

OrthoPediatrics Corp. (KIDS) Q1 2023 Earnings Call Transcript

WARSAW, Ind., May 01, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2023.

OrthoPediatrics Corp. Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will OrthoPediatrics (KIDS) Report Negative Earnings Next Week? What You Should Know

WARSAW, Ind., April 20, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced the release of its new Cannulated Screw System for the RESPONSE™ Scoliosis portfolio. The RESPONSE 5.5/6.0 Cannulated Screw system is a complete portfolio of instruments and implants and represents the Company's 47th surgical system and it's continued commitment to leading innovation in pediatric orthopedics.

OrthoPediatrics Corp. Announces Launch of RESPONSE™ 5.5/6.0 Cannulated Screw System

WARSAW, Ind., April 17, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2023 financial results on Monday, May 1, 2023, after the market closes. OrthoPediatrics will host a conference call on Tuesday, May 2, 2023, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report First Quarter 2022 Financial Results on May 2, 2023

WARSAW, Ind., April 03, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the upcoming 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023.

OrthoPediatrics Corp. to Participate at the 22nd Annual Needham Virtual Healthcare Conference

WARSAW, Ind., March 31, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced its leading sponsorship at the European Pediatric Orthopaedic Society (“EPOS”) annual meeting in Krakow, Poland. The company hosted an exhibit for OrthoPediatrics, Pega Medical, and MD Orthopaedics as well as a surgeon luncheon.

OrthoPediatrics Corp. Leading Sponsorship at Annual EPOS Meeting

OrthoPediatrics Corp (NASDAQ:KIDS ) Q4 2022 Results Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group David Bailey - President and Chief Executive Officer Fred Hite - Chief Financial Officer and Chief Operating Officer Conference Call Participants Rick Wise - Stifel Institutional Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler & Co. Michael Matson - Needham & Company David Turkaly - JMP Securities Samuel Brodovsky - Truist Securities Operator Good morning and welcome to OrthoPediatrics Corporation Fourth Quarter and Full-Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

OrthoPediatrics Corp (KIDS) Q4 2022 Earnings Call Transcript

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -45.45% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for OrthoPediatrics Stock (KIDS)